Madrigal Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 1503.78, 2250.63, 3032.7, 3989.71, 4574.56 ], "ebit_estimate": [ -192.33, 325.28, 843.03, 1584.62, 2391.03 ], "ebitda_estimate": [ -166.78, 403.35, 1435.55, null, null ], "net_income_estimate": [ -190.61, 314.78, 808.08, 1373.56, 2017.23 ], "per_share_eps_estimate": [ -6.85, 10.11, 26.26, 45.97, 66.42 ], "eps_nri_estimate": [ -6.92, 9.96, 26.56, 45, 65.1 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 19.5, 41.54, 85.81, null, null ], "pretax_income_estimate": [ -194.79, 329.32, 871.21, 1608.6, 2473.29 ], "operating_cash_flow_per_share_estimate": [ 5.62, 16.53, 41.17, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -28.65, 59.83, 64.71, null, null ], "gross_margin_estimate": [ 90.73, 90.83, 90.77, 89.95, 91 ], "operating_cash_flow_estimate": [ 163.16, 479.9, 1195.25, null, null ], "pettm_estimate": [ 0, 53.07, 20.44, 11.68, 8.08 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "47.09", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 47.09, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 53.64, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.08, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 350.14, 391.82, 441.37, 474.1, 533.47, 580.2, 649.31, null ], "ebit_estimate": [ -77.65, -29.65, -2.96, -10.6, 28.89, 92.45, 192.57, null ], "ebitda_estimate": [ -114.84, -21.14, 66, null, null, null, null, null ], "net_income_estimate": [ -74.1, -39.06, -6.55, -6.02, 33.3, 96.21, 195.69, null ], "per_share_eps_estimate": [ -2.44, -1.02, 0.04, 0.38, 1.63, 2.59, 4.25, null ], "eps_nri_estimate": [ -2.56, -1.27, -0.12, 0.38, 1.63, 2.59, 4.25, 1.07 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -77.5, -29.99, -8.62, -5.52, 34.8, 98.71, 198.69, null ], "operating_cash_flow_per_share_estimate": [ 6.14, 11.42, 20.23, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 91, 91, 91, 91, 91, 91, 91, null ], "operating_cash_flow_estimate": [ 178.26, 331.55, 587.32, null, null, null, null, null ], "pettm_estimate": [ 0, 524.12, 115.77, 60.71, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "47.09", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 47.09, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": 53.64, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -1.08, "future_operating_cash_flow_per_share_estimate_growth": null }